Phase 1 Results of Zilebesiran Published in the New England Journal of Medicine

Phase 1 Results of Zilebesiran Published in the New England Journal of Medicine

Results from the Phase 1 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension, were published in the New England Journal of Medicine (NEJM).

Read the manuscript



SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.